Hartung HP - Search Results

1

Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.

Dietrich M, Koska V, Hecker C, Göttle P, Hilla AM, Heskamp A, Lepka K, Issberner A, Hallenberger A, Baksmeier C, Steckel J, Balk L, Knier B, Korn T, Havla J, Martínez-Lapiscina EH, Solà-Valls N, Manogaran P, Olbert ED, Schippling S, Cruz-Herranz A, Yiu H, Button J, Caldito NG, von Gall C, Mausberg AK, Stettner M, Zimmermann HG, Paul F, Brandt AU, Küry P, Goebels N, Aktas O, Berndt C, Saidha S, Green AJ, Calabresi PA, Fischer D, Hartung HP, Albrecht P. Dietrich M, et al. Among authors: hartung hp. Brain. 2020 Apr 1;143(4):1127-1142. doi: 10.1093/brain/awaa062. Brain. 2020. PMID: 32293668

2

New immunopathologic insights into multiple sclerosis.

Hemmer B, Kieseier B, Cepok S, Hartung HP. Hemmer B, et al. Among authors: hartung hp. Curr Neurol Neurosci Rep. 2003 May;3(3):246-55. doi: 10.1007/s11910-003-0085-y. Curr Neurol Neurosci Rep. 2003. PMID: 12691630 Free PMC article. Review.

3

Current disease-modifying therapies in multiple sclerosis.

Kieseier BC, Hartung HP. Kieseier BC, et al. Among authors: hartung hp. Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138. Semin Neurol. 2003. PMID: 12894379 Review.

4

Biphasic form of experimental autoimmune neuritis in dark Agouti rats and its oral therapy by antigen-specific tolerization.

Jung S, Gaupp S, Korn T, Köllner G, Hartung HP, Toyka KV. Jung S, et al. Among authors: hartung hp. J Neurosci Res. 2004 Feb 15;75(4):524-35. doi: 10.1002/jnr.10879. J Neurosci Res. 2004. PMID: 14743436

5

Are statins a treatment option for multiple sclerosis?

Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Neuhaus O, et al. Among authors: hartung hp. Lancet Neurol. 2004 Jun;3(6):369-71. doi: 10.1016/S1474-4422(04)00770-7. Lancet Neurol. 2004. PMID: 15157852 Review.

6

Osteopontin, a macrophage-derived matricellular glycoprotein, inhibits axon outgrowth.

Küry P, Zickler P, Stoll G, Hartung HP, Jander S. Küry P, et al. Among authors: hartung hp. FASEB J. 2005 Mar;19(3):398-400. doi: 10.1096/fj.04-1777fje. Epub 2004 Dec 29. FASEB J. 2005. PMID: 15625076

7

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, Sommer N, Hartung HP, Hemmer B. Cepok S, et al. Among authors: hartung hp. Brain. 2005 Jul;128(Pt 7):1667-76. doi: 10.1093/brain/awh486. Epub 2005 Mar 30. Brain. 2005. PMID: 15800022

8

Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.

Rice GP, Hartung HP, Calabresi PA. Rice GP, et al. Among authors: hartung hp. Neurology. 2005 Apr 26;64(8):1336-42. doi: 10.1212/01.WNL.0000158329.30470.D0. Neurology. 2005. PMID: 15851719 Review.

9

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.

Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP. Hemmer B, et al. Among authors: hartung hp. Lancet Neurol. 2005 Jul;4(7):403-12. doi: 10.1016/S1474-4422(05)70117-4. Lancet Neurol. 2005. PMID: 15963443 Review.

10

Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.

Hartung HP, Kieseier BC, Hemmer B. Hartung HP, et al. J Neurol. 2005 Nov;252 Suppl 5:v30-7. doi: 10.1007/s00415-005-5006-3. J Neurol. 2005. PMID: 16254700 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,122 results

Search Page